Mark J Ginski

US Patent:

8501816, Aug 6, 2013

Filed:

Oct 12, 2011

Appl. No.:

13/272031

Inventors:

Blake Paterson - Baltimore MD, US
Mark Ginski - Baltimore MD, US
Brendan Canning - Ellicott City MD, US

Assignee:

Cerecor, Inc. - Baltimore MD

International Classification:

A61K 31/13
A61K 9/20

US Classification:

514662, 514663, 514579, 514849, 514850, 424435, 424464, 424465

Abstract:

Memantine compositions and methods of use are described herein. In some embodiments, the compositions comprise memantine and an absorption enhancer, or memantine and an elimination enhancer, or memantine and an absorption enhancer and an elimination enhancer.

US Patent:

20040167203, Aug 26, 2004

Filed:

Jan 22, 2004

Appl. No.:

10/762446

Inventors:

Benjamin Kibalo - Monmouth Junction NJ, US
Richard Couch - Chevy Chase MD, US
Mark Ginski - Frederick MD, US
Ali Keshavarz-Shokri - Rockville MD, US
Caren Bancroft - Germantown MD, US

International Classification:

A61K031/385
A61K031/198
A61K031/19

US Classification:

514/440000, 514/561000, 514/557000

Abstract:

Disclosed are new compounds that increase the absorption of pharmaceutical agents across mucous membranes. These absorption enhancers allow higher bioavailability of administered drugs. The enhancers advantageously have low or no cytotoxicity.

US Patent:

20070249537, Oct 25, 2007

Filed:

Apr 27, 2007

Appl. No.:

11/741355

Inventors:

Benjamin Kibalo - Borough NJ, US
Richard Couch - Bryn Mawr PA, US
Mark Ginski - Perry Hall MD, US
Ali Keshavarz-Shokri - San Diego CA, US
Caren Bancroft - Germantown MD, US

International Classification:

A61K 47/12
A61K 31/549
A61K 31/7052
A61P 43/00
A61K 38/00
A61K 38/16

US Classification:

514012000, 514002000, 514223200, 514044000, 514784000

Abstract:

Disclosed are new compounds that increase the absorption of pharmaceutical agents across mucous membranes. These absorption enhancers allow higher bioavailability of administered drugs. The enhancers advantageously have low or no cytotoxicity.

US Patent:

20100279954, Nov 4, 2010

Filed:

Nov 11, 2009

Appl. No.:

12/616638

Inventors:

BLAKE PATERSON - BALTIMORE MD, US
MARK J. GINSKI - PERRY HALL MD, US

Assignee:

ALBA THERAPEUTICS CORPORATION - BALTIMORE MD

International Classification:

A61K 38/08
A61P 1/00

US Classification:

514 218

Abstract:

Enteric compositions comprising one or more tight junction agonists and/or one or more tight junction antagonists are provided. Compositions of the invention may comprise a delayed-release coating disposed over a tight junction agonist and/or tight junction antagonist layer which may be disposed over an inert core. Delayed-release coatings may be substantially stable in gastric fluid and substantially unstable in intestinal fluid, thus providing for substantial release of the tight junction agonist and/or antagonist from the composition in the duodenum or jejunum of the small intestine.

US Patent:

20130122086, May 16, 2013

Filed:

Apr 18, 2012

Appl. No.:

13/449819

Inventors:

Blake Paterson - Baltimore MD, US
Mark J. Ginski - Perry Hall MD, US

Assignee:

Alba Therapeutics Corporation - Baltimore MD

International Classification:

A61K 9/14
A61K 9/48
A61K 38/08
A61K 9/20

US Classification:

424460, 424468, 424491, 514 217

Abstract:

Enteric compositions comprising one or more tight junction agonists and/or one or more tight junction antagonists are provided. Compositions of the invention may comprise a delayed-release coating disposed over a tight junction agonist and/or tight junction antagonist layer which may be disposed over an inert core. Delayed-release coatings may be substantially stable in gastric fluid and substantially unstable in intestinal fluid, thus providing for substantial release of the tight junction agonist and/or antagonist from the composition in the duodenum or jejunum of the small intestine.

US Patent:

20140200271, Jul 17, 2014

Filed:

Jul 2, 2013

Appl. No.:

13/933666

Inventors:

- Baltimore MD, US
Mark Ginski - Perry Hall MD, US
Brendan Canning - Ellicott City MD, US

Assignee:

Cerecor, Inc. - Baltimore MD

International Classification:

A61K 31/245
A61K 31/137
A61K 45/06
A61K 31/09
A61K 31/045
A61K 31/135
A61K 31/13

US Classification:

514537, 514648, 514655, 514662

Abstract:

Memantine compositions and methods of use are described herein. In some embodiments, the compositions comprise memantine and an absorption enhancer, or memantine and an elimination enhancer, or memantine and an absorption enhancer and an elimination enhancer.